EH3A Amarin Corporation Plc Sponsored ADR

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and full year 2024 results followed by Q&A on Wednesday, March 12th, 2025, at 8:00 a.m. ET.

The conference call with management will follow the release of the Company’s fourth quarter 2024 financial results in the pre-market hours on March 12th.  

Conference Call and Webcast Information: 

 

Access to the live call: 

Go to the investor relations section of the Company's website at 

Dial in within the United States: 888-506-0062

International dial in: 973-528-0011

Access Code: 575561



Access to replay: 

Dial in within the United States: 877-481-4010 

International dial in: 919-882-2331  

Access Code: 51859



A replay of the call will also be available through the Company's website shortly after the call. 

About Amarin

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.   

Availability of Other Information About Amarin 

Amarin communicates with its investors and the public using the company website () and the investor relations website (), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. 

Amarin Contact Information   

Investor & Media Inquiries:

Mark Marmur

Amarin Corporation plc





EN
19/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amarin Corporation Plc Sponsored ADR

 PRESS RELEASE

Amarin Announces Plan to Initiate a Ratio Change Under Its American De...

Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program 1-For-20 Ratio Change Initiated to Increase Per Share Market Price of Amarin’s ADSs in Effort to Maintain Nasdaq Listing DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced its intent to effect a ratio change on its American Depositary Shares (“ADS”) from one (1) ADS representing one (1) ordinary share, to the new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change"). The effective date of th...

 PRESS RELEASE

Amarin Reports Fourth Quarter Financial Results & Business Update and ...

Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action  -- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million -- -- Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of Commitment to Strategic Focus, Operational Streamlining, Prudent Cash Management, and Growing Global Momentum of VASCEPA®/VAZKEPA® (icosapent ethyl) Franchise -- -- Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing -- -- Company to Host Confe...

 PRESS RELEASE

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- ...

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering -- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Very Well-Controlled Low-Density Lipoprotein Cholesterol (

 PRESS RELEASE

Amarin Receives National Reimbursement for VAZKEPA® in Austria

Amarin Receives National Reimbursement for VAZKEPA® in Austria -- Austrian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Risk of Cardiovascular Events in Eligible Patients -- -- Effective 1 April 2025, Austrian Reimbursement Marks 10th National Reimbursement for VAZKEPA® in Europe, Supporting Amarin’s Continued Growth and Development Across the Continent -- DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced that Austria’s Health Authorities have appro...

 PRESS RELEASE

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results a...

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and full year 2024 results followed by Q&A on Wednesday, March 12th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s fourth quarter 2024 financial results in the pre-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch